BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
Divi’s Laboratories Ltd. is one of the largest generic active pharmaceutical ingredient manufacturers globally and has a successful track record of executing custom synthesis business for innovator customers.
Strong positioning of the company will help in monetising the growth opportunity in API and contract research and manufacturing services space given its stellar execution track record and being one of the preferred suppliers.
Further, recent and planned capex of approximately Rs 22 billion reinforces our view as Divis is known for expanding capacities with very high business visibility.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR